Integrating DNA Microarray and Protein Microarray with Next-Generation Sequencing

Biochips market was valued at $14,303 million in 2024 and is projected to reach $48,365 million by 2035, growing at a CAGR of 11.8% from 2025 to 2035. Next-generation sequencing (NGS) is a massively parallel sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA. NGS has revolutionized the biological sciences, allowing labs to perform a wide variety of applications and study biological systems at a level never before possible. Integrating biochips with Next-Generation Sequencing (NGS) technologies has change genomic research and personalized medicine by enhancing data acquisition speed and providing deeper insights into genetic mutations and molecular mechanisms.

Browse the full report description of “Biochips Market Size, Share & Trends Analysis Report, By Type (DNA Chips, Lab-on-a-Chip, Protein Chips, and Others), By Fabrication Technology (Microarrays and Microfluidics), By End-User (Hospitals and Diagnostic Centers, Academic and Research Institutes, and Biotechnology and Pharmaceutical Companies) Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/biochips-market

Government agencies and international organizations have recognized the potential of combining biochips with NGS and have invested significantly in this area. In United States, the National Institutes of Health (NIH) has allocated substantial funding to projects that integrate biochip technology with NGS to advance precision medicine. Similarly, the European Union's Horizon Europe program has dedicated resources to support research in genomics and biochip advancements, aiming to foster innovation and improve healthcare outcomes across member states.

Recent development 

• In May 2024, IDT and Molecular Health entered a global multi-year agreement to integrate their NGS capabilities. This collaboration combines IDT's Archer NGS research assay platform with Molecular Health's variant annotation and reporting software, aiming to streamline NGS workflows and accelerate cancer research discoveries.

• In November 2024, Precision for Medicine and Agena Bioscience Announced a strategic partnership focused on improving the detection of mutations not identified by NGS alone. By utilizing Agena's MassARRAY technology and Precision for Medicine's biospecimen resources, the collaboration aims to enhance molecular profiling in challenging lung tumor samples, thereby advancing diagnostic capabilities in oncology research. 

• Roche Diagnostics and China's CapitalBio signed a memorandum of understanding to develop new microarray-based products for molecular diagnostic applications. This partnership emphasizes automating and enhancing Roche's NimbleGen microarray workflow and exploring the application of NGS technology in medical diagnostics, with a focus on education and product development across China.

Key Players and Innovations

Key players operating in the market include Bio-Rad Laboratories, Inc., Illumina Inc., Danaher Corp., Agilent Technologies, Inc., and PerkinElmer Inc.  To survive in the market, these market players adopt different marketing strategies such as mergers and acquisitions, product launches, and geographical expansion.

Market Coverage

• The market number available for – 2024-2035

• Base year- 2024

• Forecast period- 2025-2035

• Segment Covered- 

o By Type

o By Fabrication Technology

o By End User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape - Bio-Rad Laboratories, Inc., Illumina Inc., Danaher Corp., Agilent Technologies, Inc., and PerkinElmer Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Biochips Market Report Segment

By Type

• DNA Chips
• Lab-on-a-Chip
• Protein Chips 
• Others

By Fabrication Technology

• Microarrays 
• Microfluidics

By End User

• Hospitals and Diagnostic Centers
• Academic and Research Institutes
• Biotechnology and Pharmaceutical Companies

Global Biochips Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Russia

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Australia and New Zealand

• ASEAN Economies

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/biochips-market